Anavex life sciences announces positive precision medicine results from up to 4-years of oral blarcamesine treatment in phase iib/iii open-label extension trial in early alzheimer's disease

New clinical precision medicine population data demonstrates up to 84.6 weeks (19.5 months) ‘time saved' by early-start

AVXL Ratings Summary

AVXL Quant Ranking